CoChat

Managing Clonal Hematopoiesis in Patients With Solid Tumors

Open access
Bolton, Kelly L., Gillis, Nancy K., Coombs, Catherine C., Takahashi, Koichi, Zehir, Ahmet, Bejar, Rafael, Garcia-Manero, Guillermo, Futreal, Andrew, Jensen, Brian C., Diaz, Luis A., Gupta, Dipti, Mantha, Simon, Klimek, Virginia, Papaemmanuil, Elli, Levine, Ross, Padron, Eric · 2019 · Journal of Clinical Oncology
Cited by 87

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

CH in the setting of cytopenias are at high risk of occult myeloid neoplasms and ultimate development of overt disease. It has been demonstrated that cases of CH with a VAF greater than or equal to 10%, multiple mutations, and spliceosome gene mutations have high positive predictive values (ranging from 0.86 to 1.0) for the presence of occult myeloid neoplasm among patients being evaluated for cytopenias. folate, haptoglobin, lactate dehydrogenase, vitamin B1, vitamin B6, vitamin B12, methylmalonic acid, and copper levels; prothrombin time or partial thromboplastin time; and international normalized ratio. Speci fi c for anemia, we suggest measuring the following: reticulocyte count, fl ow cytometry for paroxysmal nocturnal hemoglobinuria (if low haptoglobin and/or high lactate dehydrogenase in appropriate clinical context), serum protein electrophoresis, and serum immuno fi xation. Speci fi c for thrombocytopenia we suggest measuring immature platelet fraction. Speci fi c for neutropenia, we suggest measuring antineutrophil antibody level. ( ‡ ) For patients anticipated to have a poor prognosis ( , 6 to 12 months) from their primary solid tumor, we would not suggest further work-up for CH. (§) Monitoringintervalcan bedeterminedby thetreatingclinician,thoughwewouldsuggest3-to 12-monthevaluations(morefrequentlyfor patients receiving ongoing cytotoxic therapy, and less frequently for patients in long-term follow-up). Current guidelines recommend targeting a blood pressure less than 130/80 mm Hg, 36 lifestyle modi fi cations, and pharmacotherapy with a thiazide diuretic, calcium channel blocker, or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Preclinical and clinical studies suggest statins have potent antiin fl ammatory effects, including suppression of interleukin-1 b release, 36 and should be prescribed to all patients with an estimated 10-year atherosclerotic CVD risk greater than 7.5%. 38,39 BM, bone marrow; CVD, cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.00331

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

Metadata

Authors
Bolton, K. L., Gillis, N. K., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R., Garcia-Manero, G., Futreal, A., Jensen, B. C., Diaz, L. A., Gupta, D., Mantha, S., Klimek, V., Papaemmanuil, E., Levine, R., & Padron, E.
Venue
Journal of Clinical Oncology
Published
2019-01-01
Volume
37
Issue
1
Pages
7-11
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2899732591
Cited by
87
References
19
FWCI
5.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.